How much funding has BioLineRx raised?

BioLineRx has raised $9.0M in total funding, most recently a Series B round.

Who are BioLineRx's investors?

BioLineRx's investors include Giza Venture Capital.

Where is BioLineRx headquartered?

BioLineRx is headquartered in Tel Aviv, Israel.

What industry is BioLineRx in?

BioLineRx operates in Biotech, Healthcare.

How many employees does BioLineRx have?

BioLineRx has 51-200 employees.

BioLineRx

IPO

Driving innovative therapeutics across the finish line.

Tel Aviv, Israel · Founded 2003 · $9.0M raised

Biotech

Healthcare

Headquarters: Tel Aviv
Employees: 51–200
Founded: 2003
Business Model: B2B

Website: biolinerx.com
Total Funding: $9.0M
Last Round: $9.0M Series BSep 2005
Rounds: 2

About

BioLineRx (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel, focused on developing life-changing therapies for oncology and rare diseases. Founded in 2003 by leaders in the Israeli life sciences industry — including Teva Pharmaceuticals, Giza, Pitango, and Hadasit — the company leverages full-spectrum drug development expertise to advance novel therapeutics from bench through clinical trials to regulatory approval. Its lead programs target glioblastoma (GLIX1) and hematologic malignancies via its approved motixafortide asset.

Summary

BioLineRx is a Biotech company based in Tel Aviv, Israel, founded in 2003. It has raised $9.0M in total across 2 rounds, most recently a $9.0M Series B round in Sep 2005. Investors include Giza Venture Capital.